ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,187.67
0.00%
US Tech 100
17,580.84
-0.18%
다우존스 지수
39,056.39
0.44%
Bitcoin
61,501.25
-1.35%
Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Sanofi (SNY)

  7. Sanofi (SNY) 뉴스

SNY

Sanofi (SNY)

Sanofi
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:SNY
일자시간출처헤드라인심볼기업
2024/04/2520:52IH Market NewsSouthwest Shares Tumble 9.6% Post $231 Million 1Q Loss, AstraZeneca Surges on 19% Annual Increase, and More on EarningsNASDAQ:SNYSanofi
2024/04/1920:31IH Market NewsParamount’s Shares Surge Following Sony and Apollo’s Joint Bid; ISS Backs Berkshire Hathaway Director Re-election, and MoreNASDAQ:SNYSanofi
2024/02/2404:02Edgar (US Regulatory)Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)).NASDAQ:SNYSanofi
2024/02/2401:15Edgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NASDAQ:SNYSanofi
2024/02/1602:09Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SNYSanofi
2024/02/1505:57Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SNYSanofi
2024/01/2604:29GlobeNewswire Inc.Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)NASDAQ:SNYSanofi
2024/01/2321:23Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SNYSanofi
2024/01/2320:05Dow Jones NewsSanofi to Buy Assets From Inhibrx in Deal Valued at Up to $2.2 Billion -- UpdateNASDAQ:SNYSanofi
2024/01/2319:40IH Market NewsWall Street Highlights: Vroom Shuts Down Online Car Sales, Ericsson Warns of Decline Outside China, and MoreNASDAQ:SNYSanofi
2024/01/2315:00PR Newswire (US)Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2BNASDAQ:SNYSanofi
2024/01/1803:49Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SNYSanofi
2024/01/0916:14Dow Jones NewsSanofi Names Brian Foard Head of Specialty-Care UnitNASDAQ:SNYSanofi
2023/12/2801:18Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SNYSanofi
2023/12/2116:25Dow Jones NewsSanofi Ends Drug Program After Late-Stage Trial in Lung Cancer FailsNASDAQ:SNYSanofi
2023/12/1921:28Dow Jones NewsInnate Pharma Shares Rise after Sanofi Exercises Licensing OptionNASDAQ:SNYSanofi
2023/12/1219:50IH Market NewsHasbro Job Cuts, Oracle’s Stock Decline, Google’s Epic Antitrust Loss, and MoreNASDAQ:SNYSanofi
2023/12/1207:18Dow Jones NewsSanofi Terminates Agreement with Maze Therapeutics Following FTC OppositionNASDAQ:SNYSanofi
2023/12/1115:50Dow Jones NewsSanofi Sees Improvement in Trial Results of Cancer Drug SarclisaNASDAQ:SNYSanofi
2023/12/0716:34Dow Jones NewsSanofi Myeloma Drug Sarclisa Met Primary Goal in Late-Stage TrialNASDAQ:SNYSanofi
2023/12/0716:20Dow Jones NewsSanofi Sees Annual Sales From New Pharma Assets Above $10.8 Billion by 2030NASDAQ:SNYSanofi
2023/12/0622:20Dow Jones NewsTrending: Merck's Multiple Sclerosis Drug Misses Expectations in Late-Stage TrialsNASDAQ:SNYSanofi
2023/12/0619:14Dow Jones NewsMerck Shares Slump After Multiple Sclerosis Drug Fails in Late-Stage TrialsNASDAQ:SNYSanofi
2023/11/3023:23Dow Jones NewsTeva Closes Collaboration Deal With Sanofi on IBD TreatmentNASDAQ:SNYSanofi
2023/11/3022:30Business WireTeva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease TreatmentNASDAQ:SNYSanofi
2023/11/2800:31Dow Jones NewsTrending: Sanofi's Notus Trial Meets Primary EndpointNASDAQ:SNYSanofi
2023/11/2716:40Dow Jones NewsSanofi Says Notus Phase 3 Trial of Dupixent Met Primary EndpointNASDAQ:SNYSanofi
2023/11/2715:30GlobeNewswire Inc.Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious DiseaseNASDAQ:SNYSanofi
2023/11/0806:01AllPennyStocks.comOrphan Drugs Worth $64 Billion by 2028 and This Micro Cap Could Have One by That TimeNASDAQ:SNYSanofi
2023/11/0722:56Dow Jones NewsSanofi Under Preliminary Probe in France Over Possible Market Manipulation, Source SaysNASDAQ:SNYSanofi
 검색 관련기사 보기:NASDAQ:SNY

최근 히스토리

NYSE
DIS
Walt Disney
CCOM
US30
US 30
FX
USDEUR
US Dollar vs Euro
NYSE
VZ
Verizon Communications
CCOM
US100
US Tech 100
NYSE
BAC
Bank of America
CCOM
US500
US 500
NASDAQ
AAPL
Apple
AMEX
XLF
Financial Select Sector
AMEX
XLE
Energy Select Sector SPDR
NASDAQ
GOOGL
Alphabet
AMEX
SPY
SPDR S&P 500
NASDAQ
TSLA
Tesla
COIN
SOLUSD
Solana
FX
USDGBP
US Dollar vs Sterling
Delayed Upgrade Clock
ADVFN Logo

대한변국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유